ERBB2 and breast carcinoma: The percentage of HER2-positive breast cancer patients receiving Trastuzumab treatment at a provincial-level hospital in Central China rose to 58.62% in the year following its inclusion in medical insurance in 2017, up from 32.91% in the preceding year [26].